We Offer Worldwide Shipping
Login Wishlist

Isoscoparin

$896

  • Brand : BIOFRON

  • Catalogue Number : BD-P0265

  • Specification : 98.0%(HPLC)

  • CAS number : 20013-23-4

  • Formula : C22H22O11

  • Molecular Weight : 462.407

  • PUBCHEM ID : 442611

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0265

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

462.407

Appearance

Powder

Botanical Source

Structure Type

Flavonoids

Category

SMILES

COC1=C(C=CC(=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O)C4C(C(C(C(O4)CO)O)O)O)O)O

Synonyms

5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one

IUPAC Name

5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one

Applications

Density

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChI=1S/C22H22O11/c1-31-13-4-8(2-3-9(13)24)12-5-10(25)16-14(32-12)6-11(26)17(19(16)28)22-21(30)20(29)18(27)15(7-23)33-22/h2-6,15,18,20-24,26-30H,7H2,1H3/t15-,18-,20+,21-,22+/m1/s1

InChl Key

KOMUHHCFAXYRPO-DGHBBABESA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:20013-23-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

Title

72nd Congress of the Italian Society of Pediatrics Florence, Italy. 16-19 November 2016

Author

Marco Braghero,corresponding author1 Annamaria Staiano,corresponding author2 Eleonora Biasin,corresponding author3 Patrizia Matarazzo,4 Silvia Einaudi,3 Rosaria Manicone,3 Francesco Felicetti,5 Enrico Brignardello,5 Franca Fagioli,3 Elisabetta Bignamini,corresponding author6 Elena Nave,6 F. Callea,corresponding author7 C. Concato,7 E. Fiscarelli,7 S. Garrone,7 M.Rossi de Gasperis,7 Patrizia Calzi,corresponding author8 Grazia Marinelli,8 Roberto Besana,8 Carlo Caffarelli,corresponding author9 Antonio Di Peri,9 Irene Lapetina,9 Patrizia Cincinnati,corresponding author10 Rosalia Maria Da Riol,corresponding author11 Mario De Curtis,corresponding author12 Lucia Dito,12 Chiara Protano,12 Susanna Esposito,corresponding author13 Dante Ferrara,corresponding author14,15 Rossella Galiano,corresponding author16 Pasquale Novellino,16 Eric Heath Kossoff,corresponding author17 Andrzej Krzysztofiak,18 Elena Bozzola,18 Laura Lancella,18 Alessandra Marchesi,18 Alberto Villani,18 Paola Lago,corresponding author19 Elisabetta Garetti,20 Anna Pirelli,21 Paola Marchisio,22 Maria Santagati,23 Stefania Stefani,23 Susanna Esposito,22 Nicola Principi,22 Valeria d’Apolito,24 Luigi Memo,corresponding author25 Angelo Selicorni,26 Vito Leonardo Miniello,corresponding author27 Lucia Diaferio,27 Antonella Palmieri,corresponding author28 Luciana Parola,corresponding author29 Ettore Piro,corresponding author30 Claudio Romano,corresponding author31 Maria Ausilia Catena,31 Sabrina Cardile,31 Oliviero Sacco,32 Donata Girosi,32 Roberta Olcese,32 Mariangela Tosca,32 Giovanni Arturo Rossi,corresponding author32 Sergio Salerno,corresponding author33 Maria Chiara Terranova,33 Francesca Santamaria,corresponding author34 Angelo Selicorni,corresponding author35,36 Giorgia Mancano,35,36 Silvia Maitz,36 Virginia A. Stallings,corresponding author37,38 Chiara Berlolaso,39 Carolyn McAnlis,37 Joan I. Schall,37 Pasquale Striano,corresponding author40 Rita Tanas,corresponding author41 Giulia De Iaco,42 Maria Marsella,43 Guido Caggese,44 Paolo Toma,corresponding author45 Piero Valentini,corresponding author46 Danilo Buonsenso,47 David Pata,46 Manuela Ceccarelli,48 Elvira Verduci,corresponding author49 Marta Brambilla,49 Benedetta Mariani,49 Carlotta Lassandro,49 Alice Re Dionigi,49 Sara Vizzuso,49 Giuseppe Banderali,49 Gianvito Panzarino,50 Claudia Di Paolantonio,50 Alberto Verrotti,50 Alberto Villani,51 Elena Bozzola,51 Laura Cursi,51 Annalisa Grandin,51 Andrzej Krzysztofiak,51 Laura Lancella,51 Raffaele Virdis,corresponding author52,53,55 Patrizia Carletti,52,54 Giovanna Weber,corresponding author56 Silvana Caiulo,56 and Maria Cristina Vigone56

Publish date

2017

PMID

30627045

Abstract

A taxonomic treatment, phylogeny based on analysis of six DNA sequence markers (ITS, ndhA intron, rpl32-trnL, rps3, rps16 intron and rps16-trnK) and classification of Muhlenbergia for Peru is given. Seventeen species and one presumed hybrid are recognised. Muhlenbergiaromaschenkoisp. nov. is newly described from the Rio Huallaga Valley, northeast of Huanuco. The type of Podosemumangustatum [≡ Muhlenbergiaangustata] clearly aligns with what we had been referring to as the hybrid between this species and M.rigida. Therefore, we adopt the next available heterotypic name, Muhlenbergiacoerulea, for what we had been calling M.angustata and change the hybrid designation to M.coerulea × M.rigida. Lectotypes are designated for Epicampescoerulea Griseb., Muhlenbergiaaffinis Trin., Muhlenbergiaberlandieri Trin., Muhlenbergiabeyrichiana Kunth, Muhlenbergiaelegansvar.atroviolacea Kuntze, Muhlenbergiaelegansvar.subviridis Kuntze and Muhlenbergiaphragmitoides Griseb.

KEYWORDS

classification, ITS, lectotypification, Muhlenbergia , Peru, phylogeny, plastid DNA sequences, Poaceae , systematics, taxonomy

Title

Revision of Muhlenbergia (Poaceae, Chloridoideae, Cynodonteae, Muhlenbergiinae) in Peru: classification, phylogeny, and a new species, M.romaschenkoi

Author

Paul M. Peterson,corresponding author1 Isidoro Sanchez Vega,2 Konstantin Romaschenko,1 Diego Giraldo-CaNas,3 and Nancy F. Refulio Rodriguez4

Publish date

2018

PMID

11461067

Abstract

Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months and 38/69 patients have died. Grade III-IV toxicity was acceptable. Leukopenia occurred in 26% of patients, thrombocytopenia in 2% and anaemia in 4%. One patient had reversible heart failure during FEC therapy. Peripheral neuropathy and arthralgia-myalgia occurred in 9% and 4% of patients, respectively and one patient had respiratory hypersensitivity during paclitaxel treatment. 9 patients did not complete therapy because of: treatment refusal (n= 1), cardiac toxicity (n= 1), early death during FEC chemotherapy (n= 1), major protocol violations (n= 4), hypersensitivity reaction (n= 1) and early death during paclitaxel chemotherapy (n= 1). The overall response rate was 65% (95% CI = 53-76), and 7% of patients had stable disease. Therapy was defined as having failed in 28% of patients because they were not evaluable (13%) or had progressive disease (15%). The median time to progression and survival are 13.2 and 23.5 months, respectively. Sequential FEC-paclitaxel is a suitable strategy for patients with metastatic breast cancer who have not been previously treated with anthracyclines and/or taxanes. In fact, it avoids major haematologic toxicity and has a good antitumour effect. © 2001 Cancer Research Campaign http://www.bjcancer.com

KEYWORDS

advanced breast cancer, anthracycline-containing regimen, paclitaxel, sequential chemotherapy

Title

A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

Author

A Riccardi,1 P Pugliese,1 M Danova,1 S Brugnatelli,1 D Grasso,1 M Giordano,2 G Bernardo,3 G Giardina,4 S Fava,5 G Montanari,6 C Pedrotti,7 G Trotti,8 E Rinaldi,9 M A Poli,10 and C Tinelli11

Publish date

2001 Jul;